122 related articles for article (PubMed ID: 11455982)
1. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
Smalley RV; Weller E; Hawkins MJ; Oken MM; O'Connell MJ; Haase-Statz S; Borden EC
Leukemia; 2001 Jul; 15(7):1118-22. PubMed ID: 11455982
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
3. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
[TBL] [Abstract][Full Text] [Related]
5. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
Smalley RV; Andersen JW; Hawkins MJ; Bhide V; O'Connell MJ; Oken MM; Borden EC
N Engl J Med; 1992 Nov; 327(19):1336-41. PubMed ID: 1406835
[TBL] [Abstract][Full Text] [Related]
6. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
Enschede SH; Shahidi H; Venugopal P; Riley MB; Huang R; Jajeh A; Preisler HD; Gregory SA
Leuk Lymphoma; 2001 Jan; 40(3-4):325-34. PubMed ID: 11426554
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Enschede SH; Porter C; Venugopal P; Gregory SA
Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
[TBL] [Abstract][Full Text] [Related]
12. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
[TBL] [Abstract][Full Text] [Related]
15. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
Tirelli U; Errante D; Van Glabbeke M; Teodorovic I; Kluin-Nelemans JC; Thomas J; Bron D; Rosti G; Somers R; Zagonel V; Noordijk EM
J Clin Oncol; 1998 Jan; 16(1):27-34. PubMed ID: 9440719
[TBL] [Abstract][Full Text] [Related]
16. Role of interferon-alfa in NHL: still controversial?
Haase-Statz S; Smalley RV
Oncology (Williston Park); 1999 Aug; 13(8):1147-59; discussion 1159-60, 1163. PubMed ID: 10499247
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
[TBL] [Abstract][Full Text] [Related]
18. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
Lichtman SM; Petroni G; Schilsky RL; Johnson JL; Perri RT; Niedzwiecki D; Sklar J; Barcos M; Peterson BA
Leuk Lymphoma; 2001; 42(6):1255-64. PubMed ID: 11911406
[TBL] [Abstract][Full Text] [Related]
19. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
20. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
